Regulus receives $488,989 grant under QTDP program

Nov 4 2010

Regulus Therapeutics Inc. announced today that it has been awarded two grants totaling $488,989 under the Federal government's Qualifying Therapeutic Discovery Project Program. The Qualifying Therapeutic Discovery Project Program was created to support research with the potential to produce new therapies and create high paying jobs. The grant funding will support preclinical development of Regulus' novel microRNA approaches to treat Hepatitis C Virus infection and fibrosis.

“The funding provides access to non-dilutive capital supporting the advancement of our preclinical microRNA programs toward the clinic.”

"We are pleased to receive maximum awards for both of the applications we submitted to this program," said Zachary A. Zimmerman, Ph.D., Director of Business Development at Regulus. "The funding provides access to non-dilutive capital supporting the advancement of our preclinical microRNA programs toward the clinic."

The Qualifying Therapeutic Discovery Project Program provides an immediate boost to the U.S. biomedical research community through targeted support of projects that have the potential to produce new therapies, address unmet medical needs and create jobs.